{"id":"liq861-inhaled-treprostinil","safety":{"commonSideEffects":[{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Throat irritation"},{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Jaw pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Treprostinil mimics the action of prostacyclin, a naturally occurring eicosanoid that promotes vasodilation and inhibits platelet aggregation. By binding to prostacyclin receptors on vascular smooth muscle cells, it reduces pulmonary vascular resistance and improves blood flow. The inhaled delivery via Liquidia's proprietary LIQ technology allows direct lung deposition with potentially improved tolerability compared to systemic routes.","oneSentence":"LIQ861 is an inhaled formulation of treprostinil, a prostacyclin analog that vasodilates pulmonary and systemic blood vessels by activating prostacyclin receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:08.123Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"}]},"trialDetails":[{"nctId":"NCT06129240","phase":"","title":"An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liquidia Technologies, Inc.","startDate":"2023-12-28","conditions":"Pulmonary Hypertension, Interstitial Lung Disease","enrollment":80},{"nctId":"NCT03992755","phase":"PHASE3","title":"Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liquidia Technologies, Inc.","startDate":"2019-07-18","conditions":"Primary Pulmonary Hypertension","enrollment":92},{"nctId":"NCT03399604","phase":"PHASE3","title":"Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil","status":"COMPLETED","sponsor":"Liquidia Technologies, Inc.","startDate":"2018-01-02","conditions":"Primary Pulmonary Hypertension","enrollment":121},{"nctId":"NCT03884465","phase":"PHASE2","title":"Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil","status":"TERMINATED","sponsor":"Liquidia Technologies, Inc.","startDate":"2019-11-11","conditions":"Pulmonary Arterial Hypertension","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inhaled treprostinil","Inhaled prostacyclin","inhaled treprostinil","inhaled prostacyclin"],"phase":"phase_3","status":"active","brandName":"LIQ861 Inhaled Treprostinil","genericName":"LIQ861 Inhaled Treprostinil","companyName":"Liquidia Technologies, Inc.","companyId":"liquidia-technologies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LIQ861 is an inhaled formulation of treprostinil, a prostacyclin analog that vasodilates pulmonary and systemic blood vessels by activating prostacyclin receptors. Used for Pulmonary arterial hypertension (PAH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}